Journal article
Individualized glycemic control for U.S. Adults with type 2 diabetes a cost-effectiveness analysis
N Laiteerapong, JM Cooper, MR Skandari, PM Clarke, AN Winn, RN Naylor, ES Huang
Annals of Internal Medicine | AMER COLL PHYSICIANS | Published : 2018
DOI: 10.7326/M17-0537
Abstract
Background: Intensive glycemic control in type 2 diabetes (glycated hemoglobin [HbA1c] level <7%) is an established, cost-effective standard of care. However, guidelines recommend individualizing goals on the basis of age, comorbidity, diabetes duration, and complications. Objective: To estimate the cost-effectiveness of individualized control versus uniform intensive control (HbA1c level <7%) for the U.S. population with type 2 diabetes. Design: Patient-level Monte Carlo–based Markov model. Data Sources: National Health and Nutrition Examination Survey 2011–2012. Target Population: The approximately 17.3 million persons in the United States with diabetes diagnosed at age 30 years or older. ..
View full abstractGrants
Awarded by National Institute of Diabetes and Digestive and Kidney Diseases
Funding Acknowledgements
Dr. Laiteerapong was supported by grant K23 DK092783 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Dr. Huang is supported by grant K24 DK105340 from the NIDDK. Drs. Laiteerapong and Huang are members of the NIDDK Chicago Center for Diabetes Translation Research at the University of Chicago (P30 DK092949). Dr. Winn was supported by the Royster Society of Fellows at the University of North Carolina at Chapel Hill.